A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
VK2735, a dual agonist targeting GLP-1 and GIP receptors, is being evaluated for weight management in obese and overweight adults with comorbid conditions. The obesity treatment market is rapidly expanding, driven by increasing prevalence rates and demand for effective therapies. VK2735's unique mechanism may provide a competitive edge over existing GLP-1 receptor agonists, particularly if it demonstrates superior efficacy and safety profiles. Viking Therapeutics, Inc. should prepare for potential partnerships or licensing opportunities based on trial outcomes, as well as consider strategies for market entry and positioning against established players in the obesity treatment landscape.
Indication: Weight Loss
Modality: protein therapy
Target: GLP-1 and GIP receptors
Sponsor: Viking Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: GLP-1 and GIP receptors
View original source fields
Condition raw: Weight Loss
Condition normalized: Weight Loss
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: GLP-1 and GIP receptors
Target normalized: GLP-1 and GIP receptors